So far, the studies on CP novel formulations are mostly on psoriasis treatment, but a few have revealed that the formulations have prospective uses for the management of other chronic skin ailments including eczema, vitiligo, contact dermatitis recurrent aphthous stomatitis, and oral lichen planus. This evidence concerns the gene CP and Eczematoid dermatitis.